Menu
Search
|

Menu

Close
X

Acorda Therapeutics Inc ACOR.OQ (NASDAQ Stock Exchange Global Select Market)

13.13 USD
+0.00 (+0.00%)
As of 4:00 PM EDT
Previous Close 13.13
Open 13.08
Volume 295,117
3m Avg Volume 295,082
Today’s High 13.26
Today’s Low 12.64
52 Week High 36.25
52 Week Low 12.55
Shares Outstanding (mil) 47.63
Market Capitalization (mil) 625.43
Forward P/E 32.73
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
471
FY17
588
FY16
520
EPS (USD)
FY18
0.401
FY17
-4.553
FY16
-0.763
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
32.73
58.10
Price to Sales (TTM)
vs sector
1.33
8.84
Price to Book (MRQ)
vs sector
1.02
4.60
Price to Cash Flow (TTM)
vs sector
20.60
40.07
Total Debt to Equity (MRQ)
vs sector
56.17
17.66
LT Debt to Equity (MRQ)
vs sector
56.07
13.97
Return on Investment (TTM)
vs sector
1.71
12.12
Return on Equity (TTM)
vs sector
3.34
13.24

EXECUTIVE LEADERSHIP

Ron Cohen
President,Chief Executive Officer, Director, Since
Salary: $791,813.00
Bonus: --
Richard Batycky
Chief Technology Officer and Site Head, Since 2014
Salary: --
Bonus: --
David Lawrence
Chief Business Operations, Principal Accounting Officer, Since 2016
Salary: $391,083.00
Bonus: $102,651.00
Jane Wasman
President - International, General Counsel, Corporate Secretary, Since 2012
Salary: $555,100.00
Bonus: $312,077.00
Burkhard Blank
Chief Medical Officer, Since 2016
Salary: $531,750.00
Bonus: $130,610.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

420 Saw Mill River Rd
ARDSLEY   NY   10502-2605

Phone: +1914.3474300

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

SPONSORED STORIES